The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

March 6, 2025

Study Completion Date

March 6, 2025

Conditions
Major Depressive DisorderMajor Depressive EpisodeSuicidal Ideation
Interventions
DEVICE

Active SAINT Stimulation

"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."

DEVICE

Sham SAINT Stimulation

"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."

Trial Locations (4)

10021

Weill Cornell Medicine, Manhattan

29425

Medical University of South Carolina (MUSC), Charleston

52242

University of Iowa, Iowa City

78712

University of Texas, Austin, Austin

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Magnus Medical

INDUSTRY

NCT03693105 - The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition | Biotech Hunter | Biotech Hunter